Cullinan Therapeutics (CGEM) provided a corporate update and shared anticipated business highlights for 2026. Highlights; Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data. Company to complete monotherapy expansion cohorts to determine recommended Phase 2 dose for CLN-049 pivotal registrational study and initiate combination study in frontline AML in Q4 2026. Zipalertinib rolling NDA submission expected to be complete in Q1 2026 and full enrollment of REZILIENT3 frontline study expected in H1 2026. Preliminary cash and investments of $439.0 million as of December 31, 2025; Runway into 2029
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEM:
- Cullinan Therapeutics price target raised to $33 from $22 at Clear Street
- Cullinan Therapeutics price target raised to $34 from $25 at Wedbush
- Buy Rating for Cullinan Management Driven by Promising CLN-049 Clinical Data and Strategic Development Plan
- Promising Outlook for Cullinan Management: Buy Rating Backed by Strong Therapeutic Developments and Financial Position
- Optimistic Buy Rating for Cullinan Management Driven by Promising CLN-049 Therapy Results